Abstract
Cardiovascular disease remains a major cause of morbidity and mortality in modern societies. While contemporary treatment modalities are making steady inroads to reduce this disease burden there remains a pressing need to vigorously explore novel therapeutic strategies. Rapid advances in our understanding of molecular pathology and the evolution of increasingly efficient gene transfer technology offer the imminent prospect of gene-based approaches to, at least, a subset of cardiovascular pathophysiologies. Initially envisaged as a treatment strategy for inherited monogenic disorders, it is now apparent that gene therapy has broader potential that encompasses acquired polygenic diseases, including many that affect the cardiovascular system. Extensive in vitro and animal studies are providing an increasingly sound scientific basis for cautious human evaluation. This review focuses on gene therapy of diseases primarily afflicting the heart, and provides an overview of gene and vector delivery systems with particular emphasis on systems suited to individual cardiac conditions. The pathophysiology underlying these conditions and molecular targets for therapeutic intervention are also reviewed.
Keywords: cardiac, myocardium, gene therapy, gene transfer, heart failure, arrhythmia
Current Gene Therapy
Title: Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Volume: 3 Issue: 5
Author(s): E. Kizana and I. E. Alexander
Affiliation:
Keywords: cardiac, myocardium, gene therapy, gene transfer, heart failure, arrhythmia
Abstract: Cardiovascular disease remains a major cause of morbidity and mortality in modern societies. While contemporary treatment modalities are making steady inroads to reduce this disease burden there remains a pressing need to vigorously explore novel therapeutic strategies. Rapid advances in our understanding of molecular pathology and the evolution of increasingly efficient gene transfer technology offer the imminent prospect of gene-based approaches to, at least, a subset of cardiovascular pathophysiologies. Initially envisaged as a treatment strategy for inherited monogenic disorders, it is now apparent that gene therapy has broader potential that encompasses acquired polygenic diseases, including many that affect the cardiovascular system. Extensive in vitro and animal studies are providing an increasingly sound scientific basis for cautious human evaluation. This review focuses on gene therapy of diseases primarily afflicting the heart, and provides an overview of gene and vector delivery systems with particular emphasis on systems suited to individual cardiac conditions. The pathophysiology underlying these conditions and molecular targets for therapeutic intervention are also reviewed.
Export Options
About this article
Cite this article as:
Kizana E. and Alexander E. I., Cardiac Gene Therapy: Therapeutic Potential and Current Progress, Current Gene Therapy 2003; 3 (5) . https://dx.doi.org/10.2174/1566523034578249
DOI https://dx.doi.org/10.2174/1566523034578249 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics Patent Selections
Recent Patents on Regenerative Medicine Myotonic Dystrophies 1 and 2: Complex Diseases with Complex Mechanisms
Current Genomics Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Current Pharmaceutical Design Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance
Current Medicinal Chemistry Sildenafil and Cardioprotection
Current Pharmaceutical Design Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Acute Cerebral Blood Flow Variations after Human Cardiac Arrest Assessed by Stable Xenon Enhanced Computed Tomography
Current Neurovascular Research Models and Methods in Cardiac Imaging for Metabolism Studies
Current Pharmaceutical Design The Role of Klotho Protein in Chronic Kidney Disease: Studies in Animals and Humans
Current Protein & Peptide Science Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology Effects of Apelin Peptides on Diabetic Complications
Current Protein & Peptide Science Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals The HGF/c-Met Receptor System Under Pathological Conditions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)